Home
Pain Therapeutics

The SAE Media Group is delighted to announce it's 19th Annual Pain Therapeutics conference which will be held in London on the 13th and 14th May 2019.

The global opioids market size was valued at $22.96bn USD in 2016 and is projected to expand at a CAGR of 4.8% between 2018 and 2025. Rising prevalence of diseases that cause chronic pain, such as cancer, lower back pain, postsurgical pain, arthritis, and fibromyalgia, is driving growth.

Join Europe's leading Pain Therapeutics Conference which will explore the cutting edge research of novel therapeutic targets in the pipeline of leading pharmaceutical companies and discuss solutions for the challenges of clinical trial design and conduct.

FEATURED SPEAKERS

Dalma Sugar

Dalma Sugar

Global Medical Affairs Director , Reckitt Benckiser
Donald Manning

Donald Manning

Chief Medical Officer, Adynxx Inc.
Geert Jan Groeneveld

Geert Jan Groeneveld

Chief Scientific Officer / Chief Medical Officer, Centre for Human Drug Research
Iain Chessell

Iain Chessell

VP & Head, Neuroscience Innovative Medicines, AstraZeneca
Karin Hygge Blakeman

Karin Hygge Blakeman

Head of Medical Affairs Nordics, Grunenthal Ltd
Kerrie Brady

Kerrie Brady

Chief Business Officer, Centrexion Therapeutics Corp
Kirk  W Johnson

Kirk W Johnson

Research Fellow, Eli Lilly and Company
Krzysztof Potempa

Krzysztof Potempa

Founder & CEO, BRAINCURES LTD
Lynn Kirkpatrick

Lynn Kirkpatrick

CEO, Ensysce Biosciences Inc.
Michael Scherz

Michael Scherz

Founder & CEO, Metys Pharmaceuticals
Neil Singla

Neil Singla

Chief Executive Officer, Lotus Clinical Research, Llc
Sigal Meilin

Sigal Meilin

Chief Scientific Officer, MD Biosciences
Theo Meert

Theo Meert

Head of R&D Global Government Grant Office, Janssen Pharmaceutica N.V.
William Schmidt

William Schmidt

Vice President, Clinical Development , Viromed

Dalma Sugar

Global Medical Affairs Director , Reckitt Benckiser
Dalma Sugar

Dalma is a senior medical leader with over 18 years of experience spanning pharmaceutical and consumer health industry, Rx and OTC, having a breadth and depth of experience with medical/clinical and regulatory/safety functions, from both strategic global and local perspective. She has built a career in a variety of roles, started in the governmental sector, then continued in Sanofi Group for 7 years also heading a clinical trial platform later as Regulatory Medical Head for the Sanofi Group leading a portfolio of oncology, cardiovascular, neuroscience, diabetes etc. In 2012 joined Reckitt Benckiser as Regional Medical & Regulatory Affairs Head and from beginning of 2016 appointed as Global Medical Affairs Director at the Category Development organization. Aspiring to live a life of contribution, she operates fearlessly with an approach to make a difference both professionally and personally. Her passion is dealing with condition management as a whole, addressing awareness/education, diagnosis, prevention and treatment/ multimodal management, where the consumer need is in the main focus, rather than just the product itself. By having an in depth understanding of strategic global and local commercial needs, she is passionate about the creation of global strategies that make sense on the ground.

Donald Manning

Chief Medical Officer, Adynxx Inc.
Donald Manning

Dr. Donald C. Manning received his PhD in Pharmacology at Johns Hopkins University where he also earned his MD. He pursued residency training in Anesthesiology, fellowship training in Regional Anesthesia and Pain Management. Dr. Manning has held clinical academic faculty positions in the Departments of Anesthesiology at Johns Hopkins and The University of Virginia. Dr. Manning is currently the Chief Medical Officer for Adynxx Inc., a research-based early stage development company developing molecular biologic approaches to pain treatment and prevention. Prior to Adynxx Dr. Manning held various senior management positions over a 20-year career in the pharmaceutical industry.

Geert Jan Groeneveld

Chief Scientific Officer / Chief Medical Officer, Centre for Human Drug Research
Geert Jan Groeneveld

Geert Jan Groeneveld was trained as a Neurologist at the University Medical Center Utrecht where he also performed his PhD on the subject: “New pharmacotherapeutic treatment strategies for Amyotrophic Lateral Sclerosis”. Before joining CHDR, Geert Jan worked on enzyme replacement therapy for Pompe Disease and on gene therapy for Parkinson's Disease at biotechnology company Genzyme. In 2009 he started to work as Research Director at the Centre for Human Drug Research (CHDR) in Leiden, responsible for research in the areas of neurology and pain. He is a board-certified clinical pharmacologist and from 2009 to 2017 held a position as staff-member at the department of Department of Neurology at the VU University Medical Center. Since 2017 he works as a neurologist in the Department of Anesthesiology of Leiden University Medical Center, where he sees patients with chronic neuropathic pain. His primary scientific interest is in early phase drug development for the treatment of neurodegenerative diseases and pain. He has published more than 45 scientific articles in peer-reviewed journals and is actively involved in the training of PhD students at CHDR. He serves on the editorial boards of the British Journal of Clinical Pharmacology and the Dutch Journal for Neurology and Neurosurgery. As of January 1st 2018 he was appointed the CSO/CMO at CHDR and is one of the members of the Board.

Iain Chessell

VP & Head, Neuroscience Innovative Medicines, AstraZeneca
Iain Chessell

Iain Chessell, VP& Head, Neuroscience Innovative Medicines and Early Development , AstraZeneca
Dr. Iain Chessell is the Head of the Neuroscience Innovative medicines unit at AstraZeneca, based in Cambridge UK, leading a cross-functional team dedicated to discovery and clinical development of the neuroscience portfolio.Dr. Chessell joined the AstraZeneca (AZ) subsidiary, MedImmune, in November 2008 as vice president, Research, with the intent of initiating neuroscience R&D at MedImmune. After building a portfolio in analgesia and neurodegeneration, in 2010 he was promoted to vice president and head of the Neuroscience Center of Excellence (CoE) and subsequently head of the AstraZeneca neuroscience innovative medicines unit. Dr Chessell also serves on the AstraZeneca IMED leadership team which has responsibility for running the AZ’s discovery and early development organisation. Prior to joining AZ, Dr. Chessell was chief executive officer at NeuroDiscovery where he completed a number of Phase 1 and Phase 2 clinical programs for analgesia. Previously, he was global head of pain R&D for GlaxoSmithKline, where he delivered a portfolio of clinical candidates, and was involved in 19 clinical development projects from Phase 1 to Phase 3. He was also responsible for review of potential in-license opportunities, and was chair of the core disease teams for pain and neurodegeneration, as well as serving as chair of the Neurology management team. Dr. Chessell also managed several high profile academic and industrial collaborations, and is author of more than 95 peer reviewed publications. Dr. Chessell received his bachelor’s degree in pharmacology from University College London, and received his doctoral degree from the Department of Neurochemistry at the Institute of Neurology, London.
 

Karin Hygge Blakeman

Head of Medical Affairs Nordics, Grunenthal Ltd
Karin Hygge Blakeman

Dr. Hygge Blakeman heads Grünenthal’s Medical Affairs department in the Nordic region and has more than 20 years in the field of pain therapeutics.
With experience ranging from target idea generation to post marketing activities for both devices and pharmaceuticals, Karin has developed expertise in most stages of the product life.
After 10 years in discovery and development at AstraZeneca, Karin spent a couple of years in the CRO arena working with contracting studies and since 2015 she has been with Medical Affairs at Grünenthal. She has a strong focus on patient engagement and a passion for driving science with business.
Karin holds a PhD in Neurophysiology from the Karolinska Institute in Stockholm.
 

Kerrie Brady

Chief Business Officer, Centrexion Therapeutics Corp
Kerrie Brady

Kerrie Brady is a founder and chief business officer of Centrexion Therapeutics. Kerrie’s career includes 30 years of experience as an international pharmaceutical executive working in both big pharma and biotech companies. Prior to joining Centrexion, Kerrie was the chief operations officer for Vallinex Inc., a company she founded as a spin out from Arcion Therapeutics, Inc., a biotech company developing topical products for the treatment of neuropathic pain. Kerrie was also the co-founder and chief operations officer for Arcion Therapeutics Inc. Previously, she was the founder, president and chief executive officer of Traxion Therapeutics, Inc., a biotech company focused on the development of new drugs to treat intractable pain. Prior to starting on the entrepreneurial path Kerrie’s experience spanned business development (KMG Japan, Entremed, Intracel), business operations (CMC for Biopharmaceutical Research), marketing and regulatory affairs (Rhone Poulenc) Kerrie holds a BPharm from Victorian College of Pharmacy, an MBA from the University of Melbourne and an M.S. in biopharmaceuticals from the University of New South Wales. In 2016, Kerrie was named to the PharmaVOICE100 Most Inspiring People for her contributions to the life-sciences industry.

Kirk W Johnson

Research Fellow, Eli Lilly and Company
Kirk  W Johnson

Krzysztof Potempa

Founder & CEO, BRAINCURES LTD
Krzysztof Potempa

Krzysztof Potempa is Founder and CEO at BRAINCURES. He is a neuroscientist with over 10 years of experience in deciphering biology from big data in academia and industry. Since August 2016, the company has built a biology- and biomarker-powered Discovery Engine that turns data questions into de-risked and accelerated translational opportunities for precision medicine. Their unique biological intelligence has been recognized with the Beanstalks 2017 Best Mental Health Startup- and Sachs BEF18 Rising Stars- Award

Lynn Kirkpatrick

CEO, Ensysce Biosciences Inc.
Lynn Kirkpatrick

Dr. Kirkpatrick has spent over 30 years in drug discovery and development, has initiated the clinical development of four novel drug candidates and now strives to rapidly bring highly novel abuse deterrent therapies to commercialization. She received a PhD in Medicinal and Biomedicinal Chemistry at the University of Saskatchewan, completed a Post-Doctoral Fellowship at the Yale University School of Medicine, and became a tenured full professor in the Department of Chemistry at the University of Regina. She co-founded three companies, has published extensively in the area of targeted drug discovery, abuse deterrent pain products and holds numerous patents for novel drugs and modalities.

Mark Field

SVP, Head Global Clinical Development , Grunenthal Gmb H
Mark Field

Michael Scherz

Founder & CEO, Metys Pharmaceuticals
Michael Scherz

Michael Scherz manages drug development and drug discovery activities at Metys Pharmaceuticals, and is spearheading the company’s search for Series A investors. He is responsible for managing the corporate budget, and
for the selection of suitable consultants for Metys’ drug development and drug discovery activities. He is
responsible for Metys’ development plans for MP-101, a newly-patented orally-active Phase II-ready small molecule intended for the treatment and prevention of neuropathic pain, in a first clinical trial for the prevention of chemotherapy-induced symptoms of peripheral neuropathy. Since creating Metys Pharmaceuticals, Scherz has worked to share Metys’ vision and strategy with its investors and consultants.
Michael Scherz graduated in 1989 from the University of Oregon with a PhD in synthetic and medicinal
chemistry. Previously, he served as vice president and life cycle leader at Actelion Pharmaceuticals, where he was responsible for the multi-functional development teams entrusted with the Phase I to Phase III clinical development of several novel therapeutic agents. His focus on innovation, team performance, and clear communication, led to the discovery of novel candidate therapeutic agents: urotensin-II antagonists, sphingosine-1-phosphate agonists, and novel calcium channel blockers; and significant advancements of the Phase I to pre-Phase III clinical projects he led. Prior to Actelion, Scherz was section head of cardiac research at Procter & Gamble Pharmaceuticals in Cincinnati, Ohio, USA; and post-doc at Hoffman-La Roche AG in Basel, Switzerland.
 

Neil Singla

Chief Executive Officer, Lotus Clinical Research, Llc
Neil Singla

Neil Singla, MD is a board-certified anesthesiologist, founder and Chief Executive Officer of Lotus Clinical Research, and a nationally recognized key opinion leader in analgesic protocol design and implementation. Dr. Singla has frequent interactions with the FDA’s Analgesics Division on behalf of clients and plays a significant role in guiding development strategies for dozens of putative analgesic agents. In the company’s 18-year history, Dr. Singla and Lotus have played a significant role in bringing several molecules to market. Dr. Singla has published extensively and is a frequent lecturer for physicians, pharmaceutical companies, and medical research institutes globally. He currently chairs the Clinical Trials Shared/Special Interest Group at both the American Pain Society (APS) and the International Association for the Study of Pain (IASP), and serves on the Clinical Research Committee at Huntington Hospital. The main focus of Dr. Singla’s academic endeavors has been to understand and analyze how the inherent variability in subjective endpoint analgesic clinical trials can be minimized. As a result, he has developed novel techniques for patient education designed to minimize variability, reduce placebo response, and increase effect size.

Sigal Meilin

Chief Scientific Officer, MD Biosciences
Sigal Meilin

Theo Meert

Head of R&D Global Government Grant Office, Janssen Pharmaceutica N.V.
Theo Meert

Prof Theo F. Meert is head of the R&D Global Government Grant office (G3O) of J&J. He is also a professor and scientific advisor/researcher at different universities: Leuven, Antwerp, Hasselt and Ghent.
During his career at J&J that started in 1981, Dr. Meert has been appointed to multiple international global functions. Within his various functions, he guided different multidisciplinary research teams, some with full development drugs, in the field of CNS, including pain.
Dr. Meert’s scientific expertise is reflected in multiple patents (>15), publications (> 243), congress communications (> 200) and invited lectures (>190). Dr. Meert obtained a Ph.D. in psychopharmacology and a Ph.D. in Medicine/Anesthesiology
 

Thor Ostenfeld

Head Clinical Development, AstraZeneca R&D Biopharmaceuticals
Thor Ostenfeld

William Schmidt

Vice President, Clinical Development , Viromed
William Schmidt

Dr. Schmidt has more than 30 years of experience in pain medicine pharmaceutical development. He is President of NorthStar Consulting, LLC, which specializes in providing advice on preclinical and clinical studies of novel analgesic drugs to pharma and biotech companies worldwide, and simultaneously part-time VP of Clinical Development for ViroMed Co., Ltd. (Seoul, South Korea). In previous assignments, Dr. Schmidt was a key member of teams leading to the development and regulatory approval of Entereg® (alvimopan), a peripherally-acting opioid antagonist, Acelex® (polmacoxib), a dual-acting COX-2 and carbonic anhydrase inhibitor, nalbuphine (Nubain®), naltrexone (ReVia®) and the oxycodone-ibuprofen formulation used in Combunox™. Dr. Schmidt received his Ph.D. in Pharmacology from the University of California, San Francisco.

sponsors

Conference agenda

clock

8:30

Registration & Coffee

clock

9:00

Co-Chair's Opening Remarks

Michael Scherz, Founder & CEO, Metys Pharmaceuticals

Kerrie Brady, Chief Business Officer, Centrexion Therapeutics Corp

clock

9:10

Clinical Development Issues for Management of Chemotherapy-Induced Symptoms of Peripheral Neuropathy

Michael Scherz, Founder & CEO, Metys Pharmaceuticals

  • Painful symptoms of chemotherapy-induced peripheral neuropathy remain a serious medical need
  • Why use patients in your CIPN trial regardless of their chemotherapy regimen?
  • Why use patients in your CIPN trial long after they have completed chemotherapy?
  • Why use composite scores in your CIPN pain trial as primary endpoint?
  • Nearly all clinical trials in the treatment or prevention of painful CIPN have failed, should we do something different?
     
  • clock

    9:50

    Gene Therapy for Painful Diabetic Neuropathy

    William Schmidt, Vice President, Clinical Development , Viromed

  • Advancement of VM202
  • Phase 3 Clinical Study for the bilateral intramuscular injections of VM202
  • Future potential for the treatment of alternative targets
     
  • clock

    10:30

    Morning Coffee

    clock

    11:00

    Headache Therapy and relevance of fast formulations

    Dalma Sugar, Global Medical Affairs Director , Reckitt Benckiser

  • What do patients want when suffering from headache
  • Relevance of fast formulations in headache therapy
  • Fast formulations are so much more - beyond just speed of therapeutic effect
  • Chronification of pain
     
  • clock

    11:40

    New approaches and struggles to develop pain products

    Theo Meert, Head of R&D Global Government Grant Office, Janssen Pharmaceutica N.V.

  • (Chronic) Pain is a still a underrecognized societal burden … this is directly reflected in the investment on R&D
  • Emerging sciences start changing the R&D in pain research
  • Despite present limitations, PPPs can be a way forwards
  • The future lies in preventive approaches … applying continuous developing technologies
     
  • clock

    12:20

    Networking Lunch

    clock

    13:20

    Demonstration of significant pain relief in subjects with painful osteoarthritis of the knee with a novel anti-NGF, anti-TNFa bispecific fusion protein

    Iain Chessell, VP & Head, Neuroscience Innovative Medicines, AstraZeneca

  • A bispecific fusion construct shows synergistic efficacy in preclinical models of pain
  • We have advanced this molecule into PhI clinical development in osteoarthritis pain patients
  • Preliminary data demonstrates dose dependent and statistically significant efficacy after a single dose
  • We will also report on preliminary safety and tolerability information
  • clock

    14:00

    Round table discussion session

  • Why is Pain, a major health care problem, not getting the right attention?
  • Public-Private Partnerships for Development of New Pain Medicines: Compare and Contrast Activities and Outcomes in US, Europe and Asia
  • FDA are abandoning the 2014 draft guidance for developing novel treatments in neuropathic pain: will the new guidelines stimulate more and more creative drug development of innovative pain therapeutics
  • From lab to clinic- why are we not more successful in predicting clinical efficacy?

     

  • Theo Meert, Head of R&D Global Government Grant Office, Janssen Pharmaceutica N.V.

    Kerrie Brady, Chief Business Officer, Centrexion Therapeutics Corp

    Michael Scherz, Founder & CEO, Metys Pharmaceuticals

    Thor Ostenfeld

    Thor Ostenfeld , Head Clinical Development, AstraZeneca R&D Biopharmaceuticals

    clock

    15:00

    Case Study: a biological intelligence approach to de-risk and accelerate drug discovery in pain:

    We present a Discovery Engine that enables biology- and biomarker-powered precision medicine through:

  • Target-biology prioritization to enable increased preclinical and clinical success
  • Pipeline management to prevent failure early and prioritize compounds with best likelihood of success
  • Prioritization of thousands of repositioning opportunities
  • Novel biomarker identification for personalized patient-drug matching
  • Krzysztof Potempa, Founder & CEO, BRAINCURES LTD

    clock

    15:40

    Afternoon Tea

    clock

    16:10

    Acute vs. Chronic Pain: Experimental Models, Regulatory Pathways and Market Opportunities

    Neil Singla, Chief Executive Officer, Lotus Clinical Research, Llc

  • US FDA regulatory pathways for approval in acute vs. chronic pain
  • Strengths and weaknesses of the various common acute and chronic pain models within each indication
  • Overview for drug developers on various potential development plans, so they can choose the best path toward a drug that is:
  • A) approved by regulators and
  • B) adopted by clinicians when it reaches the market 

     

     

  • clock

    16:50

    Found in translation: therapy for the disease of pain rather than nociceptive masking

    Donald Manning, Chief Medical Officer, Adynxx Inc.

  • Targeting the pathologic response to trauma or injury would specifically address sensitization rather than protective nociception
  • Inhibition or modulation of nociceptive network disorders at the genomic level can be an efficient therapeutic approach to acute and chronic pain
  • Data from transcription factor decoy clinical studies will be discussed along with selective targeting of therapy based on patient characteristics
  • clock

    17:30

    Co-Chair’s Closing Remarks and Close of Day One

    Kerrie Brady, Chief Business Officer, Centrexion Therapeutics Corp

    Michael Scherz, Founder & CEO, Metys Pharmaceuticals

    clock

    8:30

    Registration & Coffee

    clock

    9:00

    Co-Chair's Opening Remarks

    Kerrie Brady, Chief Business Officer, Centrexion Therapeutics Corp

    Michael Scherz, Founder & CEO, Metys Pharmaceuticals

    clock

    9:10

    Molecular Neurosurgery – CNTX-4975 for Chronic Pain

    Kerrie Brady, Chief Business Officer, Centrexion Therapeutics Corp

  • CNTX-4975 a different paradigm for drug treatment
  • Overcoming challenges in clinical trial design and implementation
  • Clinical trial results to date in knee osteoarthritis and path forward
  • Going beyond the knee
  • clock

    9:50

    Introduction of a Novel, Modified Post-Operative Pain Model in Pigs

    Sigal Meilin

    Sigal Meilin, Chief Scientific Officer, MD Biosciences

  • A highly relevant and sensitive model for the assessment of novel nerve block therapeutics
  • This model allows for the perineural injection of the candidate compound in volumes similar to those used in human subjects
  • We will show the difference in dermal nerve density in different locations using immunohistochemistry data as well as behavioral read-outs with this model
  • clock

    10:30

    Morning Coffee

    clock

    11:00

    Demonstrating pharmacodynamic effects of new analgesic compounds early in clinical drug development

    Geert Jan Groeneveld, Chief Scientific Officer / Chief Medical Officer, Centre for Human Drug Research

  • Demonstrating proof-of-pharmacology early in the clinical study phase hugely decreases the failure rate in drug development.
  • Evoked pain test in healthy subjects can be used to quantify effects of analgesic effects of new drugs that are being developed for acute but also chronic and neuropathic pain.
  • New pharmacological mechanisms are being targeted that could lead to superior analgesic drugs, possibly replacing opioids or leading to the need for lower dose levels of opioids.
  • These new pharmacological mechanisms often need dedicated methods to demonstrate target engagement of new compounds in the early clinical study phase of a new drug.
  • This presentation will focus on evoked pain tests in healthy subjects, but also on laser evoked potentials, axonal threshold tracking and transcranial magnetic stimulation that can be used to demonstrate pharmacological effects of new analgesic drugs in healthy subjects and patients with pain.
     
  • clock

    11:40

    Finally launch - now what?

    Karin Hygge Blakeman, Head of Medical Affairs Nordics, Grunenthal Ltd

  • The importance of the SmPC
  • Who pays for what?
  • Education
  • clock

    12:20

    Networking Lunch

    clock

    13:20

    An Opioid with no abuse potential and overdose protection, dream or reality? Introducing TAAPTM / MPARTM technologies

    Lynn Kirkpatrick, CEO, Ensysce Biosciences Inc.

  • The challenge of opioid development
  • TAAP/MPAR novel mechanism of abuse deterrence and overdose protection
  • Clinical update lead TAAP product PF614
  • clock

    14:00

    Delivering new therapies to patients for the treatment of migraine: The Story of the 5-HT1F Agonist Lasmiditan

    Kirk  W Johnson

    Kirk W Johnson, Research Fellow, Eli Lilly and Company

  • Serotonin agonists for the acute treatment of migraine
  • Introduction to the 5-HT1 family of receptors, particularly 5-HT1F receptor
  • Preclinical data characterizing selective 5-HT1F agonists and presently available therapies
  • Clinical data summarizing the efficacy of Lasmiditan
     
  • clock

    14:40

    Afternoon Tea

    clock

    15:10

    Delivering new therapies to patients for the treatment of migraine: The Story of CGRP

    Kirk  W Johnson

    Kirk W Johnson, Research Fellow, Eli Lilly and Company

    • The timeline of key events linking CGRP to migraine
    • The development of small versus large molecule inhibitors
    • Broader learnings and implications for other therapies in development for migraine
     

    clock

    15:50

    Panel Discussion: Translational and transitional challenges in new analgesic drug development

  • The shift in translational pain research
  • Overcoming the challenges in translational medicine
  • Bridging the gap between development stages
  • Kerrie Brady, Chief Business Officer, Centrexion Therapeutics Corp

    Kirk  W Johnson

    Kirk W Johnson, Research Fellow, Eli Lilly and Company

    Krzysztof Potempa, Founder & CEO, BRAINCURES LTD

    clock

    17:10

    Co-Chair’s Closing Remarks and Close of Day Two

    Kerrie Brady, Chief Business Officer, Centrexion Therapeutics Corp

    Michael Scherz, Founder & CEO, Metys Pharmaceuticals


    Global Medical Affairs Director
    Reckitt Benckiser
    Chief Medical Officer
    Adynxx Inc.
    Chief Scientific Officer / Chief Medical Officer
    Centre for Human Drug Research
    VP & Head, Neuroscience Innovative Medicines
    AstraZeneca
    Head of Medical Affairs Nordics
    Grunenthal Ltd
    Chief Business Officer
    Centrexion Therapeutics Corp
    Research Fellow
    Eli Lilly and Company
    Founder & CEO
    BRAINCURES LTD
    CEO
    Ensysce Biosciences Inc.
    SVP, Head Global Clinical Development
    Grunenthal Gmb H
    Founder & CEO
    Metys Pharmaceuticals
    Chief Executive Officer
    Lotus Clinical Research, Llc
    Chief Scientific Officer
    MD Biosciences
    Head of R&D Global Government Grant Office
    Janssen Pharmaceutica N.V.
    Head Clinical Development
    AstraZeneca R&D Biopharmaceuticals
    Vice President, Clinical Development
    Viromed

    Sponsors and Exhibitors

    Official Media Partner

    Supporters

    NEW: Speaker Interview - GEERT JAN GROENEVELD, Centre for Human Drug Research

    Download

    Preliminary Attendees

    Download

    Theme Summaries for two-day agenda

    Download

    Speaker interview with Krzysztof Potempa, BRAINCURES Ltd

    Download

    Speaker Interview - Neil Singla, Lotus Clinical Research

    Download

    Speaker interview with William Schmidt, Viromed

    Download

    Speaker Interview - Michael Scherz, Metys Pharmaceuticals

    Download

    Speaker Interview with Lynn Kirkpatrick, Ensysce Biosciences

    Download

    Speaker Interview with Iain Chessell, AstraZeneca

    Download

    Speaker Interview with Dalma Sugar, Reckitt Benkiser

    Download

    2018 Speaker Presentation - Innopain

    Download

    2018 Speaker Presentation - Novartis

    Download

    2018 Speaker Presentation - Centrexion Therapeutics

    Download

    Pain Therapeutics 2019 2-day Workshop

    Download

    Pain Therapeutics 2019 2-day Programme

    Download

    Pain Therapeutics 2019 Speaker Biographies

    Download

    Pain Therapeutics 2019 Co-chair Invite Letter

    Download

    Past Attendee List for Pain Therapeutics

    Download

    Pain Therapeutics 2019 Brochure

    Download

    Sponsors and Exhibitors


    Centre for Human Drug Research

    Sponsors and Exhibitors
    http://www.chdr.nl/

    Since 1987, CHDR has developed into a unique research organisation specialising in early phase studies which combines knowledge and academic collaborations with operational excellence in clinical trial services. CHDR's strong track record in analgesic and pain research allows us to offer an efficient route towards proof of concept in patients.



    Lotus Clinical Research

    Sponsors and Exhibitors
    http://www.LotusCR.com

    Lotus Clinical Research is a specialty analgesic CRO, research site, and regulatory consulting firm supporting all phases of discovery for analgesic treatments, focused on improving the scientific accuracy of analgesic programs. Led by Dr. Neil Singla, Lotus focuses on optimizing design/conduct of clinical trials in pain, providing scientific leadership at every step of the development process.


    MD Biosciences

    Sponsors and Exhibitors
    https://www.mdbneuro.com

    MD Biosciences Neuro is a preclinical and translational contract research organization (CRO) offering services for drug development in the field of neurology and pain research. We understand that finding a trust-worthy preclinical partner is a top priority for drug developers and believe that you should have confidence in the partner you choose. That's why we are dedicated to providing each client valued expertise and advice, experience for flawless execution, and flexibility to meet the needs of rapidly changing requirements.

    With a presence in the innovation hubs of Cambridge, Massachusetts and with state of the art laboratories in Israel, our team is dedicated to building collaborative programs and creating lasting partnerships in the biotechnology community.


    Media Partners


    ACNR

    Official Media Partner
    http://www.acnr.co.uk

    ACNR (Advances in Clinical Neuroscience & Rehabilitation) is one of the most widely read publications in the neurology field in the UK. It provides concise review articles, specialist reviews of core papers from international journals, conference news, book reviews, short accounts of best management practice, case reports, news of awards/appointments and more. This independently produced journal is available free of charge to members of the profession, and we welcome your input.


    Pain News

    Official Media Partner
    https://www.britishpainsociety.org/pain-news-1/

    The British Pain Society Newsletter Pain News is published quarterly and is edited by Dr Arasu Rayen. Members of the Society will receive a free copy and are encouraged to contribute to the content.


    Genetic Engineering News

    Official Media Partner
    http://www.genengnews.com

    Genetic Engineering & Biotechnology News (GEN) is the most authoritative and widely read biotechnology news publication in the world.Published 21 times a year,GEN's unique news and technology focus include the entire bioproduct life cycle from early-stage R&D to applied research and bioprocess through to commercialization. GEN is the only publication that provides the full range of the biotechnology market coverage in areas such as omics, drugs and biomarker discovery, bioprocessing, clinical research, molecular diagnostics and biobusiness. For a free subscription go to: http://www.genengnews.com/subscriptions.aspx


    The British Journal of Pain

    Official Media Partner
    http://bjp.sagepub.com/

    The British Journal of Pain is the official journal of the British Pain Society. It provides scientists and clinicians in pain medicine with peer-reviewed review articles and expert opinions on all aspects of pain management from basic science to its clinical application including pain physiology, pharmacology and interventions. This journal provides content of multidisciplinary interest and reviews and forecasts important issues and trends in the management of acute and chronic pain.

    Media Partners


    MedTube

    Supporters
    https://medtube.net/



    Bentham Science

    Supporters
    http://www.benthamscience.com/

    Bentham Science Publishers is a major STM journal publisher of 130 plus print and online journal. Out of these, 40 journals have already registered good IMPACT FACTORS as per Journal Citation Reports® 2017. These titles have extensive readership mostly in Europe and North America. For a detailed profile please visit our website at http://www.benthamscience.com. Besides, Bentham Science publishes eBooks in all areas of Science, Technology and Medicine. Our eBooks provide professionals, academicians, corporate researchers, graduates and undergraduates worldwide with the most current information in their subject areas of interest. Our eBooks are also available in the ePub and Kindle formats besides the PDF edition here http://ebooks.benthamscience.com/. Bentham is offering attendees of this conference discounts on its publication. For more information click here


    Farmavita

    Supporters
    https://farmavitar.com

    FarmavitaR+ is the professional network of experts and service providers. Network is gathering local consultants from 90 countries in Europe, Asia, North America, Latin America, Australia and Africa. Management of international, multi-centre projects is our core competence. FarmavitaR+ is providing solutions related to pharmaceutical, medical device, food supplement and cosmetic products. Scope of services is related to solutions for product development, quality assurance, clinical trials, product registration, portfolio analysis, lifecycle management, vigilance/risk management, pricing/reimbursing, market access and promotional compliance. FarmavitaR+ is brand name of Farmavita Regulanet Ltd. Visit https://farmavitar.com for more information. Outsource anything you can think of!


    Technology Networks

    Supporters
    http://go.technologynetworks.com/subscribe-to-newsletters

    Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com


    Swiss Biotech Association

    Supporters
    http://www.swissbiotech.org/

    The Swiss Biotech Association (SBA) is the national industry association for biotechnology, including pharmaceuticals, diagnostics, agriculture, food, cosmetics, environmental biotechnology, and specialty chemicals. Members are companies active in modern biotechnology, such as R&D, Production, Marketing and Sales, Finance, Services and Consulting. SBA provides a networking platform for Life Science clusters, academic and federal institutions the like. Founded in March 1998, the Association grows steadily.


    Contract Biotechnology

    Supporters
    http://www.contract-biotechnology.com

    Contract-Biotechnology.com is a web-based platform for laboratory outsourcing solutions. It is an online R&D matching tool that connects Scientifics and service and product providers worldwide. The platform Contract-Biotechnology.com would help you in the process of finding the right partner saving time and money, because with one single and secure application you would be able to receive multiple quotes quickly, keeping your contact information confidential. Contract-Biotechnology.com is the new Collaboration Network Model for Discovery Research and Development. Contract-Biotechnology.com team has extensive experience working for pharmaceuticals, biotechs, universities and academic research institutes and can help you addressing your key gaps.


    International Pharmaceutical Industry

    Supporters
    http://www.ipimediaworld.com

    IPI gives you an insight into all areas of Biopharm, Medical, Pharmaceutical and Healthcare. IPI provides a proven supportive means of communication to the Pharmaceutical, Bio Pharmaceutical, Nutraceutical and Medical Devices industry, incorporating the latest in research and technology innovations, regulatory guidelines, marketing and communication strategies.


    Biocompare

    Supporters
    http://www.biocompare.com

    Biocompare.com is the leading resource for up-to-date product information, product reviews, and new technologies for life scientists. Biocompare combines an in-depth knowledge of life science products and new technologies with the power of the Internet to offer scientists the most dynamic, relevant, and innovative media-based marketplace for life science information.


    Drug Discovery Today

    Supporters
    http://www.drugdiscoverytoday.com/

    Drug Discovery Today covers the whole of the preclinical drug discovery process. The reviews are cutting edge, written by experts in their respective fields and cover all aspects of drug discovery from genomic and proteomic approaches, computational drug design, medicinal chemistry and the translation of these sciences to therapies.


    Gate2Biotech

    Supporters
    http://www.gate2biotech.com

    Gate2Biotech is a portal that unites biotechnological community in Central Europe. It covers all the news in the field of biotechnology. Thanks to the the portal the companies engaged in the field can easily search for research institutions and other partners to solve technical problems they are facing and here they can also present their services offer to potential partners from the Czech Republic and abroad. Gate2Biotech portal serves as a bridge connecting scientific and commercial sector. It incorporates offices and support organizations dedicated to promoting transfer of innovative technologies into a unified communication platform of Czech and international biotechnologies. As a mediator of information it draws attention to biotechnologies and support of their application and transfer into practice. It also functions as a tool for encouraging non-professionals (especially scientists and students) towards innovative business or applied research.


    Copybook - Pharmaceutical

    Supporters
    http://www.copybook.com/pharmaceutical

    Copybook is a global business network with many pharmaceutical events, exhibitions and seminars. We encourage business-to-business transactions and work tirelessly to gain our customers new business contracts worldwide. You can add events, companies and associations for free. When you are a member, you can add your company to the events listed in order to encourage other visitors to arrange meetings and appointments at those events to facilitate new business contracts. Want to see how we can increase your business network and transactions? SIGN UP FOR FREE today! Copybook – Your Global Business Network


    Mednous

    Supporters
    http://www.MedNous.com

    MedNous is a print publication and website about medical innovation in Europe. It carries exclusive interviews with companies that are at the forefront of medical technology, as well as contributor articles from prominent practitioners. Our mission is to identify significant advances in medicine and to explain how this innovation is being commercialised. In doing so, we talk to venture capitalists about what products and platforms they are supporting. We report on how regulators cope with the accelerating pace of innovation. And we regularly cover the latest developments in the discovery and development of new medical concepts in the area of antibodies, vaccines, small molecules, regenerative medicine and nanomedicines. MedNous combines the English word for medicine with the Greek word for intellect. And those with nous are readers of our publication. Visit our website: www.mednous.com


    Pharmaceutical Technology

    Supporters
    http://www.pharmaceutical-technology.com

    Pharmaceutical-technology.com is the only website focusing specifically on issues relevant to pharmaceutical professionals working with technology, be it development, engineering, IT or production. Pharmaceutical-technology.com brings you the latest in industry projects and updates, along with the news, views and trends that leading professionals – from senior executives to manufacturing managers and heads of procurement – require to stay on top of their field.


    Drug Target Review

    Supporters
    http://www.drugtargetreview.com

    Drug Target Review’s quarterly magazine, website and annual events program provides high quality content with peer-written articles that are submitted exclusively by the world’s most respected scientists in their field. This attracts a committed base of readers, users and delegates made up of senior decision-makers from the life science and drug discovery industries at the top pharmaceutical companies, as well as academics and scientists from the top research institutes across the globe.


    European Biotechnology Network

    Supporters
    http://european-biotechnology.net/

    The European Biotechnology Network is dedicated to facilitating co-operation between professionals in biotechnology and the life sciences all over Europe. The non-profit organisation brings research groups, universities, SMEs, large companies and indeed all actors in biotechnology together to build and deliver partnerships.


    Drug Development Technology

    Supporters
    http://www.drugdevelopment-technology.com

    Drugdevelopment-technology.com covers every aspect of the drug development and research process, from conception to pre-FDA approval. Our global network of journalists updates the site with the latest and most significant industry developments. This coverage allows us to provide everyone - from senior management through to research and QA staff – with in-depth reviews of the latest projects, advance notice of new product releases and analysis of the latest procedural and legislative developments.


    Labiotech.eu

    Supporters
    https://goo.gl/DRE2Gp

    Labiotech.eu is the leading digital media covering the European Biotech industry. Over 100,000 monthly visitors use it to keep an eye on the business and innovations in biotechnology. Hope you'll enjoy reading our stories!


    Pharmavision

    Supporters
    http://www.pharmavision.co.uk

    PharmaVision offers a consultancy service providing independent pharmaceutical thematic research to the healthcare industry, the investment community and competitive intelligence specialists. We perform due diligence research and provide expert commentary in healthcare. Our reports combine scientific analysis in drug delivery, R&D technologies and pharmaceutical products including patient modelling, product/technology forecasts and market trends evaluation.


    Swiss Biotech Association

    Supporters
    http://www.swissbiotech.org/

    The Swiss Biotech Association (SBA) is the national industry association for biotechnology, including pharmaceuticals, diagnostics, agriculture, food, cosmetics, environmental biotechnology, and specialty chemicals. Members are companies active in modern biotechnology, such as R&D, Production, Marketing and Sales, Finance, Services and Consulting. SBA provides a networking platform for Life Science clusters, academic and federal institutions the like. Founded in March 1998, the Association grows steadily.

    Copthorne Tara Hotel

    Scarsdale Place
    Kensington
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download

    Title


    Description

    Download

    Title


    Description


    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    Group Booking

    Please complete the below form and a member of SAE Media Group’s booking team will be in contact within 24 hours

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SAE Media Group

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smgconferences.com Email: events@saemediagroup.com
    Registered in England - SMi Group Ltd trading as SAE Media Group




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data.privacy@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out

    Fill in your details to download the brochure

    By submitting this form you agree to our privacy policy and consent to receiving communications, you may opt out at any time.